Search

Your search keyword '"Naila Kaudeer"' showing total 2 results
Start Over Author "Naila Kaudeer"
2 results on '"Naila Kaudeer"'

1. Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma

Author

Liz Darlison, John Edwards, Apostolos Nakas, Nick A Maskell, Wendy Underwood, Chris Rogers, Matthew Callister, David Waller, Richard Milton, Victoria Ashford-Turner, Paul Taylor, Claire Matthews, Victoria Hughes, Kelvin Lau, Alan Kirk, Robert C Rintoul, Elizabeth A Stokes, Kate Ashton, Daisy Elliott, Rosie Harris, Marie Kirwan, Juliette Novasio, Sara Waplington, Eric Lim, Holly Mckeon, Charlotte Jacobs, Laura White, Mary O’Brien, Judith Moore, Louise Li, Nicola Mills, Sanjay Popat, Suzanne Miller, Nadia Yousaf, D A Fennell, Clinton Ali, Andrea Bille, Liz Fuller, Andreea Ionescu, Manjusha Keni, Pek Koh, Talal Mansy, Dakshinamoorthy Muthukumar, Tony Pope, Amy Roy, Riyaz Shah, Jonathan Shamash, Zacharias Tasigiannopoulos, Sarah Treece, Katherine Joyce, Barbara Warnes, Athanasia Gravani, Rachel Brophy, Nicola Farrar, Jane Elliott, Philip Noyes, Louise Nelson, Sara Tenconi, Laura Socci, Hilary Wood, Helena Hanratty, Helena Stanley, Robert Rintoul, Amy Gladwell, Jenny Castedo, Amanda Stone, Charlotte Ingle, Hayley Hewer, Eleanor Aynsley, Andrea Watson, Alison Hassall, Masuma Begum, Christopher Worth, Ellie Piggott, Elizabeth Nadin, Yvonne Summers, Raffaele Califano, Laura Cove-Smith, Matt Evison, Maria Blinston, Amal Ismail, Rachel Chant, Asmita Desai, Ian Morgan, Victoria Lake, Nichola Harris, Simon Hodge, Nadza Tokaca, Adam Januszewski, Avani Athauda, Anisha Ramessur, Emily Grist, Niamh Colman, Michael Flynn, Joan Joyce, Sarah Vaughan, Maria Piga, Derya Sahin, Agnieszka Yongue, Emma Turay, Jaishree Bhosle, Rajiv Kumar, Charlotte Milner-Watts, Jessica Brown, David Walder, Alexandros Georgiou, Xiaorong Wu, Naila Kaudeer, Kroopa Joshi, Michael Davidson, Shelize Khakoo, Bee Ayite, Kathryn Priest, James Dobbyn, Vasanthi Prathapan, Deborah McCrimmon, Natalie Ash, Alison Norton, Bianca Peet, Libby Hennessy, and Rosemary Johnson

Subjects
Medicine
Abstract

Introduction Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality of life. Currently, only two surgical trials have been performed which found that neither extensive (extra-pleural pneumonectomy) or limited (partial pleurectomy) surgery improved survival (although there was some evidence of improved quality of life). Therefore, clinicians are now looking to evaluate pleurectomy decortication, the only radical treatment option left.Methods and analysis The MARS 2 study is a UK multicentre open parallel group randomised controlled trial comparing the effectiveness and cost-effectiveness of surgery—(extended) pleurectomy decortication—versus no surgery for the treatment of pleural mesothelioma. The study will test the hypothesis that surgery and chemotherapy is superior to chemotherapy alone with respect to overall survival. Secondary outcomes include health-related quality of life, progression-free survival, measures of safety (adverse events) and resource use to 2 years. The QuinteT Recruitment Intervention is integrated into the trial to optimise recruitment.Ethics and dissemination Research ethics approval was granted by London – Camberwell St. Giles Research Ethics Committee (reference 13/LO/1481) on 7 November 2013. We will submit the results for publication in a peer-reviewed journal.Trial registration numbers ISRCTN—ISRCTN44351742 and ClinicalTrials.gov—NCT02040272.

Published
2020
Full Text
View/download PDF

2. Systemic treatment of brain metastases in non-small cell lung cancer

Author

Urska Janzic, Anna Minchom, Naila Kaudeer, Simon Page, C. Milner-Watts, Jaishree Bhosle, Liam Welsh, I. Locke, Merina Ahmed, Natalia Vidal, Mary O'Brien, Marco Perna, and Fiona McDonald

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Antineoplastic Agents, Disease, Asymptomatic, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Molecular Targeted Therapy, Prospective cohort study, Lung cancer, Protein Kinase Inhibitors, Chemotherapy, business.industry, Brain Neoplasms, Immunotherapy, medicine.disease, Prognosis, Clinical trial, 030104 developmental biology, 030220 oncology & carcinogenesis, medicine.symptom, business
Abstract

Brain metastases (BrMs) are associated with significant morbidity and are found in up to 50% of patients with advanced non-small cell lung cancer (NSCLC). Most of the literature focuses on symptomatic BrMs, with a lack of baseline brain imaging in asymptomatic patients. Unfortunately, much of the data on local treatments with or without systemic treatment is retrospective. Clinical trials of systemic treatments largely exclude patients with BrMs. Chemotherapy is an active treatment for BrM with response rates in the brain similar to other sites of disease. Targeted systemic treatments in patients with driver mutations (EGFR and ALK-MET to date) have impressive central nervous system (CNS) penetrance and response rates. Unfortunately, no prospective data can currently guide the timings or modality of local therapies with systemic treatments in these patients who have a high incidence of CNS disease, but retrospective data suggest that early local therapies may give better intracranial progression-free survival (ICPFS). Recent immunotherapy trials have included patients with BrMs. These patients have largely been pre-treated with local therapies and are asymptomatic. Thus, the current standard is becoming, early local therapies before or in conjunction with immunotherapy agents. The approach seems to be safe. Prospective studies are needed in NSCLC BrMs patients to make sure any benefit from local therapies on the ICPFS and quality of life is not overlooked. Here we report what we think are reasonable conclusions from the available data and make suggestions for future clinical trials in the management of NSCLC BrMs.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results